Short-term fasting to reduce nausea and vomiting from chemotherapy
Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy
This study tests if short-term fasting for three days can help reduce nausea and vomiting in people receiving strong chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Saint-Pierre) |
| Trial ID | NCT04141514 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of short-term partial fasting on nausea and vomiting experienced by patients undergoing highly emetogenic chemotherapy. Participants will be divided into two groups: one practicing partial fasting for three days around their chemotherapy sessions, and the other continuing their usual diet. The study will assess the intensity and frequency of nausea and vomiting, as well as other factors such as quality of life and treatment compliance, over four chemotherapy sessions.
Who should consider this trial
Good fit: Ideal candidates are patients starting treatment with ABVD or AVD chemotherapy protocols who are able to provide informed consent.
Not a fit: Patients with diabetes, recent gastric ulcers, or significant weight loss may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly alleviate nausea and vomiting for patients undergoing chemotherapy, improving their overall treatment experience.
How similar studies have performed: While fasting has been explored in various contexts, this specific approach to managing chemotherapy-induced nausea and vomiting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient starting a treatment by chemotherapy ABVD or AVD * patient affiliated to a social security scheme * patient who gives his informed consent before any procedure related to the study Exclusion Criteria: * patient with diabetes * patient with recent gastric ulcer * patient with low BMI (less than 18,5 for patients under 70 or less than 21 for patient over 70) * albuminemia \<35 * patient wiht loss weight \> 10% in 6 months * pregnant or lactating women * chronic alcoholism * unable to understand the objectives and risks of the study * patient with psychiatric desorder, under guardianship or under judicial protection * patient who cannot read
Where this trial is running
Saint-Pierre
- CHU de la Réunion — Saint-Pierre, France (Recruiting)
Study contacts
- Principal investigator: Marie-Elora MUSSARD — CHU de La Réunion
- Study coordinator: Mélanie BEGORRE
- Email: melanie.begorre@chu-reunion.fr
- Phone: +262 (0)262 90 78 85
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.